ZIMHI (naloxone HCl injection, 5 mg/0.5 mL)
Emergency treatment of known or suspected opioid overdose
ApprovedActive
Key Facts
Indication
Emergency treatment of known or suspected opioid overdose
Phase
Approved
Status
Active
Company
About ZMI Pharma
ZMI Pharma is a private, commercial-stage biotech company founded in 2017 that has successfully brought a differentiated naloxone product to market. Its flagship product, ZIMHI, is a 5mg/0.5mL intramuscular naloxone injection, which it touts as the highest dose of naloxone available in an intramuscular auto-injector format. The company's strategy is centered on addressing the limitations of existing overdose rescue kits in the face of potent synthetic opioids like fentanyl by offering a rapid, high-dose alternative. ZMI Pharma appears to be a single-product company navigating the competitive and price-sensitive generic drug and overdose reversal market.
View full company profile